-1.11%
10.82%
-7.28%
-30.44%
122.75%
-90.49%
16.93%
AI Spotlight on NVAX
Company Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.
It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate.Novavax, Inc.was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Market Data
| Last Price | 8.91 |
| Change Percentage | -1.11% |
| Open | 9.06 |
| Previous Close | 9.01 |
| Market Cap ( Millions) | 1427 |
| Volume | 1219391 |
| Year High | 23.86 |
| Year Low | 3.53 |
| M A 50 | 8.71 |
| M A 200 | 11.0 |
Financial Ratios
| FCF Yield | -7.78% |
| Dividend Yield | 0.00% |
| ROE | 44.82% |
| Debt / Equity | -44.32% |
| Net Debt / EBIDTA | 157.30% |
| Price To Book | -2.71 |
| Price Earnings Ratio | -5.01 |
| Price To FCF | -12.85 |
| Price To sales | 1.61 |
| EV / EBITDA | -5.02 |
News
- Jan -30 - New Strong Buy Stocks for January 30th
- Jan -28 - New Strong Buy Stocks for January 28th
- Jan -27 - Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
- Jan -22 - Wall Street Analysts Predict an 81.61% Upside in Novavax (NVAX): Here's What You Should Know
- Jan -15 - Novavax (NVAX) Rises But Trails Market: What Investors Should Know
- Jan -08 - Here's why vaccine stocks are surging in 2025
- Jan -08 - Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death
- Jan -08 - Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?
- Dec -13 - Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
- Dec -12 - Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report?
- Dec -11 - NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
- Dec -10 - Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
- Dec -05 - Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
- Dec -05 - 2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
- Dec -04 - Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln
- Dec -04 - Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
- Nov -27 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- Nov -27 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
- Nov -26 - Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?
- Nov -22 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Vaccines
Expected Growth : 10.47 %
What the company do ?
Novavax's innovative vaccines use recombinant nanoparticle technology to stimulate immune responses, providing protection against infectious diseases like COVID-19, influenza, and RSV.
Why we expect these perspectives ?
Novavax's 10.47% growth driven by increasing demand for innovative vaccines, successful clinical trials, and strategic partnerships. Strong pipeline of vaccine candidates, including COVID-19 and influenza vaccines, fuels growth. Government stockpiling and procurement agreements, as well as expanding global distribution network, contribute to revenue growth.
Novavax, Inc. Products
| Product Range | What is it ? |
|---|---|
| NanoFlu | A nanoparticle-based quadrivalent influenza vaccine candidate |
| NVX-CoV2373 | A recombinant spike protein-based COVID-19 vaccine candidate |
| ResVax | A respiratory syncytial virus (RSV) fusion protein nanoparticle vaccine candidate |
| NanoFlu-H1N1 | A nanoparticle-based H1N1 influenza vaccine candidate |
| V114 | A pneumococcal conjugate vaccine candidate |
Novavax, Inc.'s Porter Forces
Threat Of Substitutes
Novavax, Inc. faces moderate threat from substitutes due to the presence of established players in the vaccine development market. However, the company's focus on innovative vaccine technologies and its strong pipeline of products may help mitigate this threat.
Bargaining Power Of Customers
Novavax, Inc. has a diverse customer base, including governments, NGOs, and private organizations, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to public health, giving it an upper hand in negotiations.
Bargaining Power Of Suppliers
Novavax, Inc. relies on a network of suppliers for raw materials, equipment, and services. While the company has some bargaining power due to its size and reputation, suppliers may still exert some pressure on prices and delivery terms.
Threat Of New Entrants
The vaccine development market is highly competitive, and new entrants may pose a significant threat to Novavax, Inc. The company's strong intellectual property portfolio and established relationships with customers and partners may help deter new entrants, but the threat remains.
Intensity Of Rivalry
The vaccine development market is highly competitive, with several established players vying for market share. Novavax, Inc. faces intense rivalry from companies like Pfizer, Merck, and GSK, which may lead to pricing pressures and increased marketing expenses.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | -37.66% |
| Debt Cost | 5.12% |
| Equity Weight | 137.66% |
| Equity Cost | 12.02% |
| WACC | 14.62% |
| Leverage | -27.36% |
Novavax, Inc. : Quality Control
Novavax, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CORT | Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a … |
| ACLX | Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which … |
| RPRX | Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, … |
| ALPN | Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline … |
| EXEL | Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Exelixis
A-Score
1-Year Total Return ->
🥈
Royalty Pharma
A-Score
1-Year Total Return ->
🥉
Corcept Therapeutics
A-Score
1-Year Total Return ->
4
Novavax
A-Score
1-Year Total Return ->
5
Alpine Immune Sciences
A-Score
1-Year Total Return ->
6
